外科理论与实践

外科理论与实践 >

2021 , Vol. 26 >Issue 02: 167 - 170

DOI: https://doi.org/10.16139/j.1007-9610.2021.02.015

综述

胆囊癌辅助治疗的研究进展

展开
  • 上海交通大学医学院附属新华医院普外科 上海市胆道疾病研究重点实验室上海市胆道疾病研究中心 上海交通大学医学院胆道疾病研究所,上海 200092

收稿日期: 2020-12-31

  网络出版日期: 2022-07-27

基金资助

国家自然科学基金(81974371)

收起

Study on gallbladder cancer adjuvant therapy

Expand

Received date: 2020-12-31

  Online published: 2022-07-27

Fold

本文引用格式

蔡晨, 龚伟 . 胆囊癌辅助治疗的研究进展[J]. 外科理论与实践, 2021 , 26(02) : 167 -170 . DOI: 10.16139/j.1007-9610.2021.02.015

参考文献

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2] Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome[J]. Clin Epidemiol, 2014, 6:99-109.
[3] Goetze TO. Gallbladder carcinoma: prognostic factors and therapeutic options[J]. World J Gastroenterol, 2015, 21(43):12211-12217.
[4] Rawla P, Sunkara T, Thandra KC, et al. Epidemiology of gallbladder cancer[J]. Clin Exp Hepatol, 2019, 5(2):93-102.
[5] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5):E359-E386.
[6] 任泰, 李永盛, 耿亚军, 等. 中国2010—2017年胆囊癌治疗模式及预后分析[J]. 中华外科杂志, 2020, 58(9):E008.
[7] Chaudhari VA, Ostwal V, Patkar S, et al. Outcome of neoadjuvant chemotherapy in “locally advanced/borderline resectable” gallbladder cancer: the need to define indications[J]. HPB (Oxford), 2018, 20(9):841-847.
[8] Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14):1273-1281.
[9] 胆道肿瘤专家委员会. CSCO胆道系统肿瘤诊断治疗专家共识(2019年版)[J]. 临床肿瘤学杂志, 2019, 24(9):828-838.
[10] Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer(BILCAP): a randomised, controlled, multicentre, phase 3 study[J]. Lancet Oncol, 2019, 20(5):663-673.
[11] Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? a phase Ⅲ multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma[J]. Cancer, 2002, 95(8):1685-1695.
[12] Edeline J, Benabdelghani M, Bertaut A, et al. Gem-citabine and oxaliplatin chemotherapy or surveillance in resected biliary tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase Ⅲ study[J]. J Clin Oncol, 2019, 37(8):658-667.
[13] Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase Ⅲ clinical trial[J]. Ann Oncol, 2019, 30(12):1950-1958.
[14] Gebbia V, Giuliani F, Maiello E, et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase Ⅱ study[J]. J Clin Oncol, 2001, 19(20):4089-4091.
[15] Nehls O, Klump B, Arkenau HT, et al. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase Ⅱ trial[J]. Br J Cancer, 2002, 87(7):702-704.
[16] Alberts SR, Al-Khatib H, Mahoney MR, et al. Gem-citabine, 5-fluorouracil, and leucovorin in advanced bi-liary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase Ⅱ trial[J]. Cancer, 2005, 103(1):111-118.
[17] Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase Ⅱ trial[J]. J Clin Oncol, 2005, 23(10):2332-2338.
[18] Nehls O, Oettle H, Hartmann JT, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase Ⅱ trial[J]. Br J Cancer, 2008, 98(2):309-315.
[19] Zhang W, Du C, Sun Y, et al. Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase Ⅱ trial[J]. Cancer Chemother Pharmacol, 2018, 82(4):655-660.
[20] Sahai V, Catalano PJ, Zalupski MM, et al. Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial[J]. JAMA Oncol, 2018, 4(12):1707-1712.
[21] Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial[J]. JAMA Oncol, 2019, 5(6):824-830.
[22] Yoo C, Han B, Kim HS, et al. Multicenter phase Ⅱ study of oxaliplatin, irinotecan, and S-1 as first-line treatment for patients with recurrent or metastatic biliary tract cancer[J]. Cancer Res Treat, 2018, 50(4):1324-1330.
[23] Wang J, Narang AK, Sugar EA, et al. Evaluation of adjuvant radiation therapy for resected gallbladder carcinoma: a multi-institutional experience[J]. Ann Surg Oncol, 2015, 22(Suppl 3):S1100-S1106.
[24] Mojica P, Smith D, Ellenhorn J. Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease[J]. J Surg Oncol, 2007, 96(1):8-13.
[25] Hyder O, Dodson RM, Sachs T, et al. Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma: a propensity score-matched surveillance, epidemiology, and end results analysis[J]. Surgery, 2014, 155(1):85-93.
[26] Mantripragada KC, Hamid F, Shafqat H, et al. Adjuvant therapy for resected gallbladder cancer: analysis of the national cancer data base[J]. J Natl Cancer Inst, 2017, 109(2):djw202.
[27] Hoehn RS, Wima K, Ertel AE, et al. Adjuvant therapy for gallbladder cancer: an analysis of the national cancer data base[J]. J Gastrointest Surg, 2015, 19(10):1794-1801.
[28] Ghidini M, Tomasello G, Botticelli A, et al. Adjuvant chemotherapy for resected biliary tract cancers: a syste-matic review and meta-analysis[J]. HPB (Oxford), 2017, 19(9):741-748.
[29] Valle JW, Lamarca A, Goyal L, et al. New horizons for precision medicine in biliary tract cancers[J]. Cancer Discov, 2017, 7(9):943-962.
[30] Verlingue L, Malka D, Allorant A, et al. Precision medicine for patients with advanced biliary tract cancers: an effective strategy within the prospective MOSCATO-01 trial[J]. Eur J Cancer, 2017, 87:122-130.
[31] Sun D, Ma J, Wang J, et al. Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer[J]. Cancer Immunol Immunother, 2019, 68(9):1527-1535.
[32] Chen X, Wu X, Wu H, et al. Camrelizumab plus gem-citabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase Ⅱ trial[J]. J Immunother Cancer, 2020, 8(2):e001240.
[33] Kim RD, Chung V, Alese OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer[J]. JAMA Oncol, 2020, 6(6):888-894.
Options
文章导航

/

〈 〉